Cronos Group is in an unusual spot for a cannabis name — the stock is quietly rallying, shorts are barely engaged, and the borrow market is among the loosest in the sector.
The price tells the headline story. CRON closed at CAD 4.45 on August 18, up 3.5% on the week and 13.5% over the past month. That monthly move is meaningful for a name that spent much of the past year grinding sideways. The most recent earnings print reinforced the momentum: when Cronos reported on August 6, the stock jumped 13.7% the next day and added another 2.4 percentage points by the end of that week — the kind of reaction that tends to attract fresh attention. The next earnings date is November 6, giving the current setup time to either consolidate or extend before the market gets another fundamental read.
Short sellers are not pressing the thesis here. Short interest is running at just 0.79% of free float — a level so low it barely registers as a bearish signal. The week-on-week change was effectively flat, and while the one-month trend shows a modest 4.5% increase in shares short, the absolute level remains trivial. The borrow market confirms there is no real conviction among shorts: availability is exceptionally wide at over 2,290%, meaning there are roughly 23 shares available to borrow for every one currently lent out. Cost to borrow has also eased sharply, dropping from a peak above 3.5% in late July to just 1.1% now — more than 60% below where it was a month ago. Together, these readings point to a market that is not fighting the rally in any meaningful way.
The structural ownership picture is the most distinctive feature of this stock. Altria Group controls 42.5% of shares outstanding — a strategic anchor position that has not changed in recent reporting periods. Beyond Altria, CEO Michael Gorenstein added 602,605 shares in the March quarter, and D.E. Shaw built a new position of roughly 758,000 shares over the same period. Pillsbury Lake Capital added over 2.3 million shares, while Arrowstreet Capital and Mackenzie Financial each initiated fresh positions by the end of June. The direction of institutional flow is broadly constructive, though positions remain small relative to Altria's dominant stake.
The Street's formal view on the stock is stale — the most recent analyst consensus data is more than five years old and carries no useful signal for current positioning. What the ORTEX factor scores do offer is a modest bearish lean on short positioning: the short score rank of 71 places CRON in the upper third of names by short sentiment intensity, even though the absolute short interest is negligible. The ORTEX short score itself has been essentially flat all month, hovering near 32 — consistent with a stock that is not attracting fresh bearish attention but also not clearing any squeeze-risk thresholds. The EV/EBITDA multiple has compressed by roughly 1.7x over the past 30 days, a sign the rally has brought the valuation in somewhat relative to recent earnings momentum.
Among close peers, ACB gained 1.4% on the week while WEED slipped 1.4% — a gentle divergence that leaves CRON as the relative outperformer in the Canadian cannabis group this week. The November earnings date is the clearest upcoming event to frame: given the strong August print and the pattern of outsized post-earnings moves, how the company manages expectations into Q3 results will likely matter more than any near-term shift in the borrow market.
See the live data behind this article on ORTEX.
Open CRON on ORTEX →ORTEX Market Intelligence content is generated by AI from a snapshot of ORTEX's proprietary data. Content is informational only and does not constitute investment advice.
